Format

Send to

Choose Destination
J Vet Intern Med. 2011 Nov-Dec;25(6):1385-90. doi: 10.1111/j.1939-1676.2011.00796.x. Epub 2011 Sep 13.

Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder.

Author information

1
Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN 47907-2026, USA.

Abstract

BACKGROUND:

Transitional cell carcinoma (TCC) of the urinary bladder of dogs can be a difficult cancer to treat, and effective therapies are limited. Vinblastine has been used in humans with TCC and has potent anti-proliferative effects against canine TCC cells in vitro.

OBJECTIVES:

To determine the antitumor activity and toxicoses of vinblastine in dogs with urinary bladder TCC.

ANIMALS:

Animals selected were 28 privately owned dogs that presented to the Purdue University Veterinary Teaching Hospital (PUVTH) with measurable, histologically confirmed TCC.

METHODS:

Prospective clinical trial: The starting vinblastine dosage was 3.0 mg/m(2) i.v. every 2 weeks. Treatment continued until cancer progression or unacceptable toxicoses occurred. Complete evaluations (physical exam, complete blood count [CBC], serum biochemical profile, urinalysis, thoracic radiography, abdominal ultrasound [US]) were performed at 8-week intervals. Urinary tract US with bladder tumor mapping was performed monthly. Toxicoses were graded according to Veterinary Co-Operative Oncology Group (VCOG) criteria.

RESULTS:

Tumor responses included 10 (36%) partial remission, 14 (50%) stable disease, and 4 (14%) progressive disease. The median progression free interval was 122 days (range, 28-399 days). The median survival time was 147 days (range, 28-476 days) from 1st vinblastine treatment to death and 299 days (range, 43-921 days) from diagnosis to death. The majority of dogs (27 of 28) did not have clinically relevant adverse effects. Seventeen of 28 (61%) dogs required dosage reductions because of neutropenia.

CONCLUSION AND CLINICAL IMPORTANCE:

Vinblastine has antitumor activity against TCC in dogs and can be considered another treatment option for this cancer.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center